SEC Form SC 13G/A filed by Freeline Therapeutics Holdings plc (Amendment)

$FRLN
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Get the next $FRLN alert in real time by email
SC 13G/A 1 freelinetherapeutics13ga.htm SC 13G/A

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. 2)*

Freeline Therapeutics Holdings plc

(Name of Issuer – as specified in its charter)

Ordinary shares, £0.0001 per share

(Title of Class of Securities)

35655L107

(CUSIP Number)

December 31, 2022

(Date of Event which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

þ        Rule 13d-1(b)

¨        Rule 13d-1(c)

¨        Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 
 

 

1

NAME OF REPORTING PERSON

Eventide Asset Management, LLC

 

2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

¨ (a)

¨ (b)

3 SEC USE ONLY
4

CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH

 

5

SOLE VOTING POWER

5,920,765

 

6

SHARED VOTING POWER

0

7

SOLE DISPOSITIVE POWER

5,920,765

 

8

SHARED DISPOSITIVE POWER

0

 

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

5,920,765

 

10

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

¨

11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

9.1%

 

12

TYPE OF REPORTING PERSON

IA

       

 

 
 

 

1

NAME OF REPORTING PERSON

Finny Kuruvilla, M.D. Ph. D.

 

2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

¨ (a)

¨ (b)

3 SEC USE ONLY
4

CITIZENSHIP OR PLACE OF ORGANIZATION

United States

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH

 

5

SOLE VOTING POWER

0

 

6

SHARED VOTING POWER

5,920,765

 

7

SOLE DISPOSITIVE POWER

0

 

8

SHARED DISPOSITIVE POWER

5,920,765

 

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

5,920,765

 

10

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

¨

11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

9.1%

 

12

TYPE OF REPORTING PERSON

IN;HC

       

 

 
 

 

1

NAME OF REPORTING PERSON

Robin C. John

 

2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

¨ (a)

¨ (b)

3 SEC USE ONLY
4

CITIZENSHIP OR PLACE OF ORGANIZATION

United States

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH

 

5

SOLE VOTING POWER

0

 

6

SHARED VOTING POWER

5,920,765

 

7

SOLE DISPOSITIVE POWER

0

 

8

SHARED DISPOSITIVE POWER

5,920,765

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

5,920,765

 

10

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

¨

11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

9.1%

 

12

TYPE OF REPORTING PERSON

IN;HC

       

 

 
 

Item 1. (a) Name of Issuer:

Freeline Therapeutics Holdings plc (the “Issuer”)

(b) Address of Issuer’s Principal Executive Offices:

Stevenage Bioscience Catalyst, Gunnels Wood Road, Stevenage, Hertfordshire, SG1 2FX, United Kingdom

Item 2. (a) Name of Persons Filing:

(i) Eventide Asset Management, LLC (“Eventide”)

(ii) Finny Kuruvilla, M.D., Ph.D. (“Kuruvilla”)

(iii) Robin C. John (“John”)

(b). Address of Principal Business Office or, if none, Residence:

Eventide, Kuruvilla and John:

One International Place, Suite 4210

Boston, Massachusetts 02110

(c). Citizenship or Place of Organization:

Eventide: Delaware

Kuruvilla: United States

John: United States

(d). Title of Class of Securities:

Ordinary shares, £0.0001 per share

 

(e). CUSIP Number:

35655L107

Item 3. If this statement is filed pursuant to sections 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

(a) [ ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

(b) [ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

(c) [ ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

(d) [ ] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);

(e) [x] An investment adviser in accordance with section 240.13d-1(b)(1)(ii)(E);

(f) [ ] An employee benefit plan or endowment fund in accordance with section 240.13d- 1(b)(1)(ii)(F);

(g) [x] A parent holding company or control person in accordance with section 240.13d- 1(b)(1)(ii)(G);

(h) [ ] A savings association as defined in section 3(b) of the Federal Deposit Insurance

Act (12 U.S.C. 1813);

 
 

(i) [ ] A church plan that is excluded from the definition of an investment company under

section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j) [ ] A non-U.S. institution in accordance with section 240.13d-1(b)(1)(ii)(J);

(k) [ ] A group, in accordance with section 240.13d-1(b)(1) (ii)(K).

If filing as a non-U.S. institution in accordance with section 240.13d-1(b)(1)(ii)(J), please specify the type of institution: __________

Item 4. Ownership:

Provide the following information regarding the aggregate number and percentage of the class of securities of the Issuer identified in Item 1.

(a). Amount beneficially owned:   
   (i) Eventide:  5,920,765
   (ii) Kuruvilla:  5,920,765
   (iii) John:  5,920,765
(b). Percent of class:   
   (i) Eventide:  9.1%
   (ii) Kuruvilla:  9.1%
   (iii) John:  9.1%
(c). Number of shares as to which the person has:   
(i)        Sole power to vote or to direct the vote:   
   (1) Eventide:  5,920,765
   (2) Kuruvilla:  0
   (3) John:  0
(ii)        Shared power to vote or to direct the vote:   
    
   (1) Eventide:  0
   (2) Kuruvilla:  5,920,765
   (3) John:  5,920,765
(iii) Sole power to dispose or to direct the disposition of:
   (1) Eventide:  5,920,765
   (2) Kuruvilla:  0
   (3) John:  0
(iv) Shared power to dispose or to direct the disposition of:
   (1) Eventide:  0
   (2) Kuruvilla:  5,920,765
   (3) John:  5,920,765
 
 

Item 5. Ownership of Five Percent or Less of a Class:

Not Applicable

Item 6.Ownership of More Than Five Percent on Behalf of Another Person:

As of December 31, 2022, Eventide Asset Management, LLC, a Delaware limited liability company located at One International Place, Suite 4210, Boston, MA 02110, is the beneficial owner of 5,920,765 shares of the Issuer's Ordinary Shares by virtue of being the investment adviser to the Eventide Healthcare & Life Sciences Fund which is a registered investment company (the "Fund").

As of December 31, 2022, the Fund held 5,920,765 shares of the Issuer's Ordinary Shares, representing 9.1% of the Issuer’s outstanding Ordinary Shares.

Item 7.Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company:

Not Applicable

Item 8. Identification and Classification of Members of the Group:

Not Applicable

Item 9. Notice of Dissolution of Group:

Not Applicable

Item 10.Certification:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

In accordance with Rule 13d-4 of the Securities Exchange Act of 1934, each of the persons filing this statement expressly disclaim the beneficial ownership of the securities covered by this statement and the filing of this report shall not be construed as an admission by such persons that they are the beneficial owners of such securities.

 
 

SIGNATURES

 

The undersigned certify, after reasonable inquiry and to the best knowledge and belief of the undersigned, that the information set forth in this Statement is true, complete and correct. The undersigned agree to the filing of this single Statement on Schedule 13G.

 

Eventide Asset Management, LLC

Date: February 10, 2023                                    By: /s/ Jennifer Reiche

Name: Jennifer Reiche

Title: Chief Compliance Officer

 

Finny Kuruvilla, M.D., Ph. D.

Date: February 10, 2023                                     By: /s/ Finny Kuruvilla, M.D., Ph. D.

Name: Finny Kuruvilla, M.D., Ph. D.

Robin C. John

Date: February 10, 2023                                     By: /s/ Robin C. John

Name: Robin C. John

 
 

 

EXHIBIT 1

WHEREAS, in accordance with Rule 13d-1(k)(1) under the Securities and Exchange Act of 1934 (the "Act"), only one joint Statement and any amendments thereto need to be filed whenever one or more persons are required to file such a Statement or any amendments thereto pursuant to Section 13(d) of the Act with respect to the same securities, provided that said persons agree in writing that such Statement or amendments thereto is filed on behalf of each of them;

NOW, THEREFORE, the parties hereto agree as follows:

Eventide Asset Management, LLC, Finny Kuruvilla, M.D., Ph. D. and Robin C. John do hereby agree, in accordance with Rule 13d-1(k)(1) under the Act, to file a Statement on Schedule 13G relating to their ownership of the Common Stock of the Issuer, and do hereby further agree that said Statement on Schedule 13G shall be filed on behalf of each of them.

Eventide Asset Management, LLC

Date: February 10, 2023                                     By: /s/ Jennifer Reiche

Name: Jennifer Reiche

Title: Chief Compliance Officer

 

Finny Kuruvilla, M.D., Ph. D.

Date: February 10, 2023                                     By: /s/ Finny Kuruvilla, M.D., Ph. D.

Name: Finny Kuruvilla, M.D., Ph. D.

Robin C. John

Date: February 10, 2023                                     By: /s/ Robin C. John

Name: Robin C. John

Get the next $FRLN alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$FRLN

DatePrice TargetRatingAnalyst
2/1/2022Overweight → Equal-Weight
Morgan Stanley
1/7/2022Neutral → Buy
Redburn
11/29/2021$10.00Buy
BTIG
8/18/2021$30.00 → $20.00Buy
HC Wainwright & Co.
8/17/2021$27.00 → $8.00Overweight → Neutral
JP Morgan
8/17/2021Overweight → Neutral
JP Morgan
More analyst ratings

$FRLN
Press Releases

Fastest customizable press release news feed in the world

See more
  • Freeline to Present New Data on its Gaucher and Parkinson's Disease Programs at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting

    Late-breaking oral presentation on results from Phase 1/2 study of FLT201 in Gaucher disease Poster presentation to highlight Freeline's GBA1 Parkinson's disease research program LONDON, April 24, 2024 (GLOBE NEWSWIRE) -- Freeline Therapeutics today announced the acceptance of multiple abstracts, including one for a late-breaking oral presentation on new clinical data from its Gaucher disease program, at the upcoming American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting taking place May 7-11, 2024 in Baltimore, Maryland. "Gaucher disease is a severe and progressive disorder that leads to a wide range of symptoms, including enlarged organs, bone pain and fractures, low bl

    $FRLN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Acquisition of Freeline by Syncona Becomes Effective

    LONDON, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (NASDAQ:FRLN) ("Freeline") and Syncona Ltd ("Syncona") today announced that, in connection with Syncona's acquisition of Freeline by way of a scheme of arrangement (the "Scheme"), the Scheme has been sanctioned by the Court and the court order (together with a copy of the scheme circular published by Freeline on January 18, 2024 (the "Scheme Circular") has been delivered to the Registrar of Companies.   Accordingly, the Scheme has become Effective in accordance with its terms and the entire issued share capital of Freeline is now owned or controlled by Syncona Portfolio Limited. Capitalized terms in this an

    $FRLN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Freeline Shareholders Approve Acquisition by Syncona

    LONDON, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (NASDAQ:FRLN) ("Freeline") and Syncona Ltd ("Syncona") today announced that Freeline's shareholders have approved the proposal for Bidco 1354 Limited ("Bidco"), a wholly owned subsidiary of Syncona Portfolio Limited ("Syncona Portfolio"), to acquire all shares of Freeline not currently owned by Syncona Portfolio for $6.50 per American Depositary Share ("ADS") in cash (the "Acquisition"). As previously announced, Freeline and Bidco entered into an implementation agreement on November 22, 2023 to implement the Acquisition by means of a scheme of arrangement pursuant to Part 26 of the UK Companies Act 2006 (the "Sche

    $FRLN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$FRLN
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$FRLN
SEC Filings

See more

$FRLN
Leadership Updates

Live Leadership Updates

See more
  • Genespire appoints Dr. Sabah Sallah as Chief Medical Officer

    Genespire appoints Dr. Sabah Sallah as Chief Medical Officer Accomplished executive with extensive preclinical and clinical gene therapy experience joins Genespire to accelerate pipeline to the clinic Milan, Italy, 7 July 2022: Genespire, a next generation gene therapy company developing first-in-class transformative therapies with advanced lentiviral vectors, today announces the appointment of Dr. Sabah Sallah MD, PhD as Chief Medical Officer. Dr. Sallah will lead the Company's clinical strategy, development and operations as Genespire progresses its novel advanced lentiviral gene therapy platforms towards the clinic. Dr. Sallah is a board-certified hematologist who has spent more than

    $FRLN
    $QURE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
  • Freeline Appoints Paul Schneider as Chief Financial Officer

    LONDON, April 19, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (NASDAQ:FRLN) (the "Company" or "Freeline") today announced that Paul M. Schneider has been appointed Chief Financial Officer (CFO), effective May 16, 2022, based in Boston. Mr. Schneider joins Freeline from Exo Therapeutics, Inc., where he served as Senior Vice President, Finance and Operations. A seasoned financial executive with more than 20 years of leadership experience in large and small private and public biopharmaceutical companies, Mr. Schneider brings an impressive track record of financial stewardship, including corporate strategy and execution, financial planning, analysis and reporting, and investor

    $FRLN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Freeline Appoints Henning R. Stennicke, PhD, as Chief Scientific Officer to Lead Research and Discovery

    LONDON, Feb. 03, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (NASDAQ:FRLN) (the "Company" or "Freeline"), a clinical-stage biotechnology company developing transformative adeno-associated virus ("AAV") vector-mediated systemic gene therapies for people with inherited systemic debilitating diseases, today announced the expansion of its executive leadership team with the appointment of Henning R. Stennicke, PhD, as Chief Scientific Officer (CSO). Dr. Stennicke has been appointed to the role of CSO effective March 1, 2022. He will be based in Stevenage, UK, and report to Michael Parini, Freeline's Chief Executive Officer, as part of the executive leadership team. As CSO, Dr.

    $FRLN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$FRLN
Financials

Live finance-specific insights

See more
  • Freeline Reports Positive Initial Clinical Data from First Cohort of Phase 1/2 GALILEO-1 Trial of FLT201, Its Novel Gene Therapy Candidate, in Gaucher Disease

    Robust increases of up to 700-fold over baseline in plasma GCase enzyme activity in first two patients treated with FLT201 Normalization of leukocyte GCase in both patients demonstrates cellular uptake from plasma FLT201 has been well tolerated, with no serious adverse events Company to host conference call today at 8 a.m. ET LONDON, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (NASDAQ:FRLN) today reported positive initial safety, tolerability and enzyme activity data from the ongoing Phase 1/2 GALILEO-1 trial evaluating FLT201, its adeno-associated virus (AAV) gene therapy candidate, in Gaucher disease. Gaucher disease is a debilitatin

    $FRLN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Freeline Reports Second Quarter 2023 Financial Results and Business Highlights

    Completed dosing in first cohort of Phase 1/2 GALILEO-1 trial of FLT201 in Gaucher disease; expect to report initial clinical data in third quarter of 2023 Extending impact of its novel GCase variant with research program for GBA1-linked Parkinson's disease Management to host conference call at 8:00 a.m. ET today LONDON, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (NASDAQ:FRLN) today reported financial results for the second quarter of 2023 and provided a business update. "FLT201 is a potential first- and best-in-class gene therapy for Gaucher disease Type 1, the most common type of the disease," said Michael Parini, Chief Exec

    $FRLN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Freeline Therapeutics to Host Second Quarter 2023 Financial Results Call

    LONDON, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (NASDAQ:FRLN) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Tuesday, August 15, 2023 to report its second quarter financial results and provide a corporate update. Participants may access this event via the teleconferencing numbers below and asking to join the Freeline call or through the webcast link here. Domestic: 1-866-524-3160International: 1-412-317-6760 While not required, it is recommended that participants join the call 10 minutes prior to the scheduled start. A live webcast of the call will also be available on the Investors section of Freeline's website at ww

    $FRLN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$FRLN
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more